Tanezumab - Pfizer/Eli Lilly

Drug Profile

Tanezumab - Pfizer/Eli Lilly

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rinat Neuroscience
  • Developer Eli Lilly; Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain; Pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 03 Nov 2017 Pfizer and Eli Lilly initiates enrolment in a follow-up, observational phase III trial for Cancer pain, Back pain and Musculoskeletal pain in USA (NCT03031938)
  • 03 Nov 2017 Adverse events and efficacy data from a phase III subcutaneous/intravenous bridging trial in Osteoarthritis presented at the 81st Annual Scientific Meeting of the American College of Rheumatology and the 52nd Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2017)
  • 13 Jun 2017 Tanezumab receives Fast Track designation for Back pain [SC,IV] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top